Invitalia has approved a Development Contract with the Avellino area Altergon Italy srl (proposing party), a company active in the sector of production and marketing of medicines and pharmaceutical preparations, and others 4 companies (members) based in Campania: Pharmaceuticals Damor SpA, Dermofarma Italia srl, Alfa In-Instruments Ltd. e Techno-Bios srl.
The investment program provides for the strengthening of the pharmaceutical and medical devices sector in Campania through the creation and/or expansion of 5 plants for the production and development of new highly innovative medical devices: plaster medical products, new transdermal technologies, fillers and injectables, diagnostic kits, creams, eye drops and biomedical instruments. The total investment amounts to 48,7 million euros - 37,4 million for industrial projects and 11,3 for the R&D project - of which 33,8 million euros of concessions granted by Invitalia. 22 new jobs are planned.
The Contract also provides for a project of Research and development (R&D) which will be carried out together with further 4 subjectsmembers: the University of Campania Luigi Vanvitelli - Department of Experimental Medicine; the Federico II University of Naples – Department of Chemical Sciences; the University of Salerno – Department of Pharmacy and the University of Naples Federico II – Department of Pharmacy.
“With this agreement – he said Dominic Arcuri, Chief Executive Officer of Invitalia – we invest in a significant industrial reality in the South, helping to consolidate the presence of important companies in a territory, such as Campania, to which Invitalia has always paid particular attention with some of its incentives to help relaunch the activities productive and entrepreneurial”. The reduction of times and the administrative simplifications guaranteed by the Development Contract - concluded Arcuri - are confirmed as strengths for companies which, also and above all in the South, want to modernize production systems and increase their competitiveness".
"It is the second project financed by Invitalia, with which we have already worked very efficiently to expand our activities in Irpinia - he added Salvatore Cincotti, CEO of Altergon – We are European leaders in the production of transdermal drugs but also present in biotechnology, with the production of hyaluronic acid with a very high degree of purity. With this new planning phase, we will reach the threshold of 100 million invested in just over ten years and we will be able to definitively consolidate the company, laying the foundations for new development goals worldwide”.
